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During the course of experimental viral oncogenesis, a number of tumor cell 
components have been found to elicit antibody responses in the host animal, 
thus being recognised as foreign. These antigenic materials have been shown to 
be specific for each particular  oncogenic virus, even when a particular  virus is 
known  to  transform  cells of different  species.  A  variety  of antigens  may be 
detected in tumors produced by the DNA viruses of cubic  symmetry: a) com- 
plete infectious virus particles produced in polyoma mouse tumors (1),  rabbit 
papillomata  (2), and in small quantities in primary SV40 hamster tumors  (3); 
b)  structural  virion  subunits produced in hamster  tumors  induced by adeno- 
virus types 12,  18, and 31  (4, 5); c) nonstructural  "T" or "neoantigens",  prob- 
ably coded by the viral genomes, which also appear dm-ing early phases of the 
lyric cycle, and are found in the adenovirus  (5, 6), SV40 (6,  7), and  polyoma 
systems (8); and d) nonstructural  cellular surface antigens,  possibly coded by 
the viral genome, normally stimulating primarily a cellular antibody response, 
and appearing in the polyoma (9, 10), SV40 (11, 12, 13), and adenovirus tumor 
systems (14,  15). Although  the relationship  between these classes of antigens 
and their possible role in oncogenesis has been studied in a number of previous 
investigations  (15, 16,  17), many points have yet to be resolved. Among these 
are the circumstances under which the host-antibody response can be deviated 
to respond predominantly to any particular class of antigen,  the precise nature 
of the nonstructural antigens, and the possible influence of antibody response to 
each class of antigen upon response to other classes of antigens  and resistance 
to tumor growth. 
Although  the  adenovirus  tumor  system has  been most  extensively  studied 
from the standpoint of the humoral antibody response to the structural virion 
and T  antigens  (4, 5,  18,  19), there has been relatively little work reported on 
the transplantation  antigen(s)  (14,  15).  More information  on the latter would 
complement the studies on virion  and T  antigens,  the extensive investigations 
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of adenovirus morphology, and the biochemistry of the lyric cycle. The present 
report  describes  experiments  on  the  adenovirus  transplantation  tumor  anti- 
gen(s)  in circumstances  by which immunity  can be produced,  on the  relation- 
ship between immunity  to  other  antigens  and  the  transplantation  antigen(s), 
and on the specificity and strength of the antigen(s). 
Materials  and  Methods 
Experimental Animals.--These  consisted  of randomly bred  golden Syrian hamsters  and 
inbred  CBA strain mice from the colonies  of the National Institute for Medical Research, 
London, England. Young adult female animals 4--8 months old were used as routine for trans- 
plantations. 
Viruses.--Stra~n 1131 of adenovirus type 12 was used throughout. This strain was originally 
isolated by Dr. M. S. Pereira from human material and has since been passed continuously in 
human embryonic kidney (HEK) ceils. Inocula prepared from concentrating and disrupting 
infected cells at 4  + cytopathogenicity routinely titered 10~-> 10  a TCIDi0/1 ml on HEK mono- 
layers. In addition, other viruses used included the prototype strains of adenovirus types 18, 
5, and 7A; SV40; and the influenza strain A2/Taiwan/1/64 (used  as allantoic fluid harvest). 
Virion subunits of adenovirus type 12 were prepared by stepwise elution on  DEAE-cellulose 
columns as described previously (20).  Doubly chromatographed preparations of antigens A 
(hexon) and C (fiber) were utilized (21). 
Tumors.--Adenovirus type 12 tumors were obtained by subcutaneous inoculation of new- 
born CBA mice with 0.05 ml of virus inocula. Typical adenovirus type tumors first appeared 
after 2 to 3 months, and at  1 yr most inoculated animals developed tumors. The CBA/A1 
tumor line with which most of these experiments were performed was derived from a  tumor 
induced by Dr. R. Taylor in a neonatally thymectomized animal. Four other tumor lines, B1, 
C1, D1, and El, were reduced by the inoculation of nonthymectomized newborn CBAs. Ham- 
ster tumors induced by adenovirus type 12  (strain 1131), the Bryan strain of Rous sarcoma 
virus (RSV), and the Harvey strain of murine sarcoma virus (MSV) were also used. 
Transplantation.--All tumor lines were maintained by serial subcutaneous implantation by 
tmear of minced tumor fragments. Tumor challenges to elicit transplantation resistance were 
carried out by intracerebral inoculation of trypsinized single cell suspensionsin0.02 ml volumes. 
Subcutaneous inoculations of tumor cell suspensions were also occasionally performed. At the 
15th transplant  passage,  a  large number of aliquots of a  cell suspension of tumor A1 were 
frozen in dimethyisulfoxide (DMSO) into liquid nitrogen.  Most subsequent  challenges with 
this tumor were performed by inoculating individual samples of thawed ceils. 
Experiments were terminated as routine i month after the last animal appeared with tumor. 
Mean latent periods of tumor development were calculated by averaging the time of tumor 
appearance  for all animals of a  given experimental group,  excluding animals that  did not 
develop tumors. 
Immunizations.--Experimental  animals  were  inoculated  with  virus  preparations  sub- 
cutaneously or intraperitoneally, Some immunizations were carried out with 1:1 or 1:2 emul- 
sions of virus in complete Freund's adjuvant, or with virus and adjuvant preparations sep- 
arately administered subcutaneously into opposite flanks.  Immunizations were also carried out 
with subthreshold doses of live isologous  tumor ceils and suspensions  of ultraviolet-irradiated 
(1.0-2.0 X  107 ergs of irradiation)  or X-irradiated  (3,500 R  in a Cobalt 50  bomb)  isologous 
tumor  cells.  Trocar implantation  of heterologous hamster  adenovirus  type  12  tumors  and 
hamster RSV and MSV tumors were also used. Immunization was also performed with sub- 
cellular fractions of isologous  mouse tumors. Crude aqueous tumor extracts (20% v/v) were 
prepared by mincing and grinding viable tumor tissue in phosphate-buffered saline followed by 
freezing and thawing several times. Immunizing subcellular fractions consisted of supernatant LEONARD  D.  BERMAN  985 
and resuspended, washed sediment after clarification of crude extracts at 2000 rpm for 1 hr. 
Other fractions consisted of resuspended, washed sediments obtained after centrifugation of 
the initial clarified extract at 20,000 rpm for 1 hr, and at 40,000 rpm for 16 hr. Top and bottom 
fractions of the supematant material were also used. 
Sera,  Lymph Node  and  Spleen  Cdls.--Sera  from tumor-bearing and immunized animals 
were collected by retroorbital puncture. Lymph node and spleen cells of immunized animals 
were collected by mincing nodes and spleens and washing tissue through a fine wire mesh. 
Adoptive  Transfers.--These  were performed by incubating mixtures of  tumor cells with 
lymph node cells,  spleen cells, or serum from immunized animals at 37  ° for 1 hr before inocu- 
lating  the mixtures intracerebrally or  subcutaneously into  experimental animals.  Prior  to 
incubation, sera were either heated at 56°C for 30 rain or fortified with equal volumes of addi- 
TABLE  I 
Incidot~e of lntra¢erebral and Subcutaneous  Takes in CBA Mouse Adenovirus  Tumor Line A1 
1 
Passage  [  Cell dose 
Intracerebral Dosage 
8 
9 
11 
10 
12 
14 
16 
19 
10  i 
2/2  2/2 
4/4 
8/8 
5/5 
4/4 
4/4 
s/s 
lO/lO 
10  3 
2/2 
2/2 
3/3 
4/6 
6/6 
4/4 
5/5 
10/10 
10~ 
O/2 
O/2 
2/4 
O/5 
1/4 
4/4 
3/5 
7/8 
Subcutaneous  Dosage 
I  10  o  5 X 10~  105  104  103 
$  2/2  2/2  0/2  0/2 
28  16/19  5/20  0/19 
tional fresh guinea pig complement. In the case of tumor-serum incubations,  an extra dose of 
serum was administered intraperitoneally 1 wk  after the initial inoculation. 
Complement  Fixation  Tests.--These  were performed  by a  dropping method  in standard 
plexiglass hemagglutination trays.  The method has been described  previously  (22).  After 
overnight incubation at 4°C  of antigen-antibody-complement mixtures, plates were brought 
to 37°C and the hemolytic system added. 
Virus Ne~raliza~ion  Tests.--These were performed by incubation at 370C  of serum-virus 
mixtures at appropriate serum dilutions for 1 hr before addition to tubes of HeLa cell mono- 
layers. The highest serum dilution showing clear inhibition of  cytopathogenic effect (CPE) 
compared with virus controls was recorded as the neutralizing titer. 
RESULTS 
Stability of tumor lines.  The A1 tumor line has been carried through 29 pas- 
sages  in  CBA  mice.  Table  I  shows  the  results  of  cell  titrations  at 
various passages by the  subcutaneous  and  intracerebral  routes.  The tumori- 986  ADENOVI.RUS  TUMOR  SYSTEM 
genicity was quite stable throughout all passage levels tested. However, there 
was  a  greater  than  lO0-fold  difference  in  the  sensitivity of  intracerebrally 
inoculated mice over subcutaneously inoculated animals.  To minimize varia- 
tions due to possible heterogeneity in a  large inoculum, the intracerebral route 
was chosen for challenge in most of the transplantation immunity experiments. 
Fig. 1 shows a mouse exhibiting the typical signs of intracerebral pressure due to 
tumor growth. The animal is hunched and listless, the fur ruffled. Other animals occa- 
sionally showed progressive paralysis of the limbs, bulging of the cranial cavity, an- 
tenor orbital displacement, lateral rotation of normal head position, or hyperexcita- 
bility. The earliest onset of these symptoms occurred 3 wk after inoculation with 10  4 
TABLE II 
Incidence of Intracerebral Takes in CBA Mouse Adencvirus Tumor Line AI 
DMS0 frozen passage 16 ceils stored in liquid N. 
Days post freezing  Cell dose 
37 UW* 
37 W~ 
45 UW 
116 UW 
153 UW 
235 UW 
262 UW 
272 UW 
298 UW 
345 UW 
10  4 
5/5 
6/6 
5/5 
5/5 
5/5 
5/6 
5/5 
7/7 
7/7 
10  a 
4/4 
4/5 
5/5 
6/6 
5/5 
6/6 
7/7 
8/8 
6/6 
8/8 
10  2 
3/5 
2/5 
4/5 
I/6 
4/6 
5/6 
O/7 
9/9 
1/6 
* UW, unwashed  cells. 
W, washed cells. 
ceils, and  once  symptoms appeared animals usually died within  a  few  days.  This 
provided a sharp, uniform end point for titrations. Prolonged survivM or tumor regres- 
sion was never observed once symptoms appeared. When 1@ or 103 tumor cells were 
administered to unimmunized control animals, most tumors appeared in 30-50 days. 
However, the appearance of growing tumor was delayed in animals given 102 cells and 
in some immunized animals. Tumors in the latter groups of animals would occasionally 
take over 100 days to make their appearance. Fig. 2 shows the cross-section of the 
brain of an animal with symptoms similar to those shown in Fig. 1. The central area 
is replaced by a large tumor mass, which on higher magnification exhibited the char- 
acteristic small-cell adenovirus tumor type histology (23). 
It was reasoned that a greater uniformity of tumor challenge could be achieved by 
continually using cells from the same tumor preparation. This was achieved by freezing 
multiple aliquots of a  single tumor cell suspension in DMSO at a  concentration of 
5 ×  105 cells/ml. Vials of cells were stored in liquid nitrogen and thawed rapidly before LEONARD  D.  BERMAN  987 
use. Table II shows the viability of frozen stored tumor cells as a function of the time 
of storage. At the 37th day of storage, tumor cells, unwashed and washed free of the 
DMSO,  were fitrated.  No  significant  difference  in  fiter was found.  Thereafter, all 
challenges  were performed with unwashed cells. It is also apparent that the tumori- 
genicity of these cells was essentially unaltered after 345 days of storage. 
Attempts  to  Demonstrate  Immunity  by  Immunization  with  Virus.--Habel- 
Sj5gren (9,  10)  type experiments were performed by immunization with serial 
dilutions  of  adenovirus  type  12.  Results  are  shown  in  Table  III.  Mice 
immunized  with  l0  T infectious  units  of  virus  were  well  protected  against 
challenge with both dilutions of A1  tumor cells.  Five of five tested sera from 
this group of mice also contained  complement-fixing antibody against adeno- 
TABLE 111 
Transplantation Immunity Induced by Varying Doses of Ad~odrus 12 
Immunizing dose* 
10r$ 
104 
lO  a 
lO  1 
None 
Intracerebral 
challenge 
Either 
10  s or 10  4 
cells 
Incidence of tumors, days after tumor challenge 
30 
0/11  0/11 
0/12  0/12 
0/11  5/11 
0112  2112 
0110  2/10 
40 
o/11 
2/12 
9/11 
11112 
7110 
50 
o111 
4/12 
11/11 
12/12 
lo/lo 
60 
o/11 
6/12 
11/11 
12/12 
lO/lO 
80 
o/11 
9/12 
11/11 
12/12 
10/10 
Challenge:  I0  s or 104  A1  mouse tumor cells.  Treatment:  100-fold serially diluted  1131 
adenovirus  12.  Initial titer: 107  TCID60. 
* TCID~0  in  human  embryonic kidney cells. 
~t Sera from five mice in this group 4  days prior to challenge had  complement fixation 
(CF) titers of 1/10,  1/40(2),  1/80, and  1/160 against a  crude adenovirus 12 preparation. 
virus type 12.  Immunization with a  100-fold diluted inoculum also gave pro- 
tection  that  was  manifested  chiefly by a  prolongation  in  the  latent  period. 
10  -4 and 10  -6 dilutions of virus were nonimmunizing. 
Since  immunization  was  demonstrated  with  whole  homologous virus,  the 
effect of soluble antigens was next studied. Table IV shows that, although there 
was some effect when 103 cells were used for challenge, only whole mature virus 
protected  upon  challenge  of  104  A1  cells.  DEAE-cellulose-chromatographed 
structural antigens,  and early harvests of infected HeLa cells containing little 
mature virus but abundant T  antigen, were much less effective. 
The specificity of immunization was also studied by immunizing with vari- 
ous viruses related  or  unrelated  to  adenovirus  type  12.  Table V  shows  that 
adenoviruses types 5 and 7, SV40, and influenza A2 did not induce resistance 
against tumor transplantation. In Experiment XXVIII, though no great differ- 
ence in tumor incidence was found, transplantation immunity  with adenovirus 988  ADENOVIRUS  TUMOR  SYSTEM 
12, and to a lesser  extent with adenovirus type 18,  could be detected through 
a prolongation of the mean latent period. 
The specificity of tumor challenge and comparative antigenicity of tumors 
TABLE IV 
Effect  of Immunization with  Viral Antigens  on Resistance to Adenovirus Mouse  Tumor  A1 
Immunization  .  Intracerebrallo,  cell dOSelO, 
None  5/5  3/6 
Complete Ad. 12  0/4  0/4 
Ad. 12 A antigen  3/4  0/4 
....  C  "  4/4  0/3 
20 hr HeLa cell Ad. 12 harvest 
44 hr HeLa cell Ad. 12 harvest 
72 hr HeLa cell Ad. 12 harvest 
None 
4/4  0/2 
3/3  0/4 
0/4  0/4 
5/5  4/6 
TABLE V 
Effect on Resistance to Mouse Adeno~irus lg Tumor Line by Prior Immunization with Various 
V~ru$e$ 
Experiment 
XXVIII 
XVlII 
Immunization 
None 
Ad. 12 (X 1) 
"  (X 3) 
hd. 18 (X 3) 
Ad. 5 (X 3) 
None 
Ad. 12 (X  1) 
Ad. 7 (X  1) 
sv4o (x l) 
Influenza A2 (X 1) 
Cell do~  Mean latent  period 
10  2  days 
9/9  55 
517  66 
5/8  79 
7/7  63 
7/7  54 
1~ or 10  z 
9/10 
3/lo 
10/10 
8/9 
8/9 
was studied by challenging adenovirus 12-1mmunized mice with five separate 
lines of CBA adenovirus 12-induced tumor. Table VI shows that all five tumor 
lines were inhibited by adenovirus type 12 immunization, and presumably each 
was carrying the transplantation  antigen.  However, each tumor exhibited  its 
own distinctive growth rate and antigencity, the two factors varying inversely. 
The time for maximum immunizing effect to occur  was found by varying 
the  interval  between  virus  administration  and  tumor  challenge.  Table  VII LEONARD D.  BERMAN  989 
shows that although there was some immunization after 1 wk, manifested by a 
delay in the mean latent period, it required at least 2 wk for the full immunizing 
effect to  be  achieved. Table  VIII  shows,  however,  that immunization with 
TABLE  VI 
Resistance of Adenovirus 12 Immunized Mice to Five CBA Mouse Adenovirus Tumors 
Tumor  Transplant  Immunization  Intracerebral tumor 
line  passage  cell dose 
A1 
B1 
C1 
D1 
El 
19  Ad. 12 
None 
Ad. 12 
None 
Ad. 12 
None 
Ad. 12 
None 
Ad. 12 
None 
I0* 
41s*  (TS)~: 
sis  (40) 
2/5  (11o) 
S/5  (so) 
4/5  (98) 
S/S  (3S) 
0/5  -- 
2/4  (60) 
1/s  (so) 
5/s  (44) 
0/s  -- 
s/s  (38) 
0/5  -- 
4/4  (63) 
0/s  -- 
4/5  (33) 
0/3  -- 
3/s  (70) 
1/s  (80) 
s/s  (s6) 
* Incidence of tumor development. 
Mean latent period (days). 
TABLE VII 
Protextion Against  Tumor Challenge Following Varying Periods of Adenovirus Imraunizagon 
Weeks between 
immunization* and 
tumor challenge~ 
4 
3 
2 
1 
Untreated control 
20 
0/4 
o/4 
o/4 
o/4 
o/5 
Days after tumor challenge 
30 
o/4 
o/4 
o/4 
o/4 
4/5 
40 
014 
0/4 
0/4 
0/4 
5/5 
5O 
0/4 
O/4 
O/4 
1/4 
5/5 
60 
o/4 
o/4 
o/4 
3/4 
5/5 
80 
O/4 
1/4 
O/4 
4/4 
S/5 
* Immunization, 0.2 ml strain 1131 adenovirus 12 intraperitoneally. 
Challenge, 104  adenovirus 12  A1  mouse tumor ceils  intracerebrally. 
emulsions of complete Freund's adjuvant and virus had less effect than immuni- 
zation with virus  alone.  This is  illustrated in Text-fig.  1 which shows  that 
heated virus or virus administered with Freund's adjuvant, either in an emul- 
sion or separately, does have an immunizing effect, although considerably less 
than that of infectious virus alone. 
Adoptive and Passive Transfer.--To investigate the nature of the immune 990  ADENOVIRUS TUMOR SYSTEM 
response, mice were immunized with virus or tumor and, after a suitable period 
of immunization,  spleen  cells, lymph node  cells,  and  serum  were  recovered 
and  incubated in vitro for  short periods of time with A1  tumor  cells before 
TABLE VIII 
Effect  of Freund's  Adjuvant on Transplantion  Immunity to Mouse Adenovirus  Tumor  Induced 
by Adenovirus  Immunizagon 
Immunizstion  Intracerebral  tumor cell dose 
V* 
V+F, 
V &F§ 
Control 
1o  4 
1/6 
4/6 
3/5 
6/6 
lO  ~ 
1/6 
3/5 
4/6 
6/6 
10  2 
0/5 
4/6 
5/7 
5/6 
* Adenovirus 12 alone, one dose. 
~; Adenovirus 12; adjuvant emulsion, one dose. 
§ Adenovirus  12 and adjuvant administered separately at different sites. 
IOO 
tO  C+/"  AvX .~'~"  -  .......  ~-  -r  Ir 
/'  /~  V~~  IU 
"",,  60"  //I///W///~~ 
0  .  ......o..~-  ..............  o 
ILl  ////  .... 
0 40"  ...c,..-  "*''*'~''" 
0  20"  ~  "  /  ..~  ..,~..:  / 
~..~. ............  ." 
O  ,b  26  3b  4b  Sb  Ob  7b  8b  ~  ,60 
DAYS 
TJ~xT-FTo. I. Effect of Freund's adjuvant on transplant immunity to mouse adenovims 
tumor induced by adenovizus immunization. Percentage of deaths p]otted against time after 
challenge with 108 and I0' intracerebral  adenovims mouse tumor cells. 4-, untreated  controls; 
29 animals. X, immunized with heated (A) adenovirus 12 (56°C, 30 min); 11 animals. O,  im- 
munized with adenovirus 12-adjuvant emulsion; 34 animals. II, immunized  with adenovirus 
12 and adjuvant at separate sites; 11 animals. •,  immunized with adenovirus 12; 37 animals. 
intracerebral inoculation of the mixtures into recipient mice. Results of these 
experiments showed that immune cells of animals sensitized by adenovirus 12, 
or to a lesser extent with subthreshold doses of A1 tumor cells, were able, upon 
incubation  with  tumor  cells,  to  limit subsequent  tumor  development in  the 
intact animal. Lymph node cells were much more potent than spleen cells in 
this regard. Table IX, which demonstrates the effect of sensitized lymph node LEONARD  D.  BERMAN  991 
cells on the A1  tumor line,  shows agreement with the results on complete in 
vivo assay (to be described) in that lymph node cells of virus-immunized ani- 
mals showed a much greater protective effect than ceils of animals immunized 
with live homologous tumor cells. Also consistent with the previously described 
results was the fact that lymph node cells from animals immunized with virus 
plus Freund's adjuvant showed no demonstrable protective action.  This was 
true  even  though  animals given virus-adjuvant emulsions  were actively im- 
TABLE  IX 
Adoptive Transfer of Adenot~rus lg Transplantation Immunity by Sensitir,  ed Lymph 
Node Cells 
CeH 
mixtures* 
io/1 
111 
Immunization 
of donors 
Ad. 12:~ 
Ad. 12  -[- Fr§ 
Tumor[[ 
Control 
Ad. 12:~ 
Ad. 12 +  Fr§ 
Tumor[[ 
Control 
20 
o17 
0/7 
0/4 
0/6 
0/8 
o/8 
0/8 
0/5 
Days after tumor challenge** 
°i° 
0/7  0/7 
0/7  7/7 
0/4  0/4 
0/6  4/6 
0/8  0/8 
o/8  7/8 
o/8  2/8 
o/s  3/s 
50 
o17 
7/7 
i/4 
6/6 
o/8 
7/8 
718 
515 
60 
0/7 
7/7 
1/4 
6/6 
0/8 
7/8 
7/8 
515 
70 
017  017 
7/7  7/7 
1/4  2/4 
616  6/6 
018  O/S 
718  7/8 
8/8  8/8 
sis  sis 
* Ratio of lymph node cells to tumor cells. 
Two doses of subcutaneous (S.Q.) adenovirus 12.  Serum titer,  1/160 versus adeno 12 
viral antigen; negative versus adeno 12 T antigen. Neutraling antibody titer,  1/640. 
§ Two doses of adenovirus 12 in complete Fretmd's adjuvant S.Q. Serum titer,  1/1280 
versus adeno  12  viral antigen; negative versus adeno 12  T  antigen. Neutraling antibody 
titer, 1/1280. 
[I Three subthreshold doses of adenovirus 12 mouse tumor  ceils S.Q. Serum titer,  1/10 
versus adeno  12  viral antigen;  negative versus adeno  12 T antigen. Neutraling  antibody 
titer,  1/10. 
** Challenge, 10  s A1 frozen mouse tumor ceils mixed with lymph node cells from immu- 
nized donors and inoculated intracerebrally. 
munized against adenovirus 12, showing both complement-fixing and neutraliz- 
ing antibody.  Complement fixation  tests also revealed the  complete absence 
of demonstrable anti-T antibody in the sera of all experimental groups of ani- 
mals regardless of whether lymph node cells showed protective action or not. 
Table X  shows the effect of repeated immunizing doses of virus upon  the 
sensitization  of lymph node  cells.  Sensitization  of lymph node  cells was not 
achieved unless  three  immunizing doses of virus were administered,  in  spite 
of the fact that one dose was sufficient to immunize in the complete in vivo 
experiments previously described. 
Numerous  tests  were  performed  to  investigate  the  effect of  various  sera 992  ADENOVIRUS TUMOR SYSTEM" 
directly on tumor  cells  or via passive  transfer.  Sera used  included  those of 
donor animals listed in Table IX, plus a  hyperimmune anti-adenovirus type 
12 rabbit serum, and an adenovirus tumor-bearing rat serum that contained a 
high titer of anti-T antibody. In no case was there any unequivocal evidence of 
either  cytotoxicity or  enhancement.  This  included  tumor-serum  incubations 
done in the presence of added complement, and those done with heated serum 
in the absence of complement. 
Attempts to Demonstrate Resistance by Immunization with Cells or Subcellular 
Fractions.--Table XI shows results of immunization with one dose of various 
preparations of whole isologous tumor cells or subcellular fractions. From these 
TABLE X 
Effect of Continued Antiviral Immunization  on Development of Cdlular Immunity to Adenovirus 
Mouse Tumor A1 by Adoptive Transfer 
Immunization 
XXIV 
XIX 
XXVIII 
20 
Control 
Ad. 12 (X 1) 
Control 
Ad. 12 (X 3) 
Control 
Ad. 12 (X 1) 
Ad. 12 (X 3) 
5o 
0/7 
0/7 
0/6 
0/7 
O/tO 
0/9 
O/lO 
Days after challenge* 
30  40 
2/7  2/7  3/7 
0/7  0/7  6/7 
4/6  4/6  6/6 
017  017  017 
2/10  8/10  8/10 
4/9  6/9  8/9 
O/lO  1/lO  3/lO 
Experiment 
6/7 
7/7 
6/6 
0/7 
lO/lO 
9/9 
6/10 
9O 
6/7 
7/7 
6/6 
0/7 
10/10 
9/9 
7/10 
~ean 
latent 
period 
days 
53 
51 
37 
42 
41 
59 
* 10/1 ratio of incubated lymph node cells to tumor cells given intracerebrally (104 lymph 
node cells/lO  8 tumor cells). 
results it can be seen that,  although there was no essential  difference in the 
incidence of tumors in immunized groups, there was some prolongation of the 
latent period in many of the immunized groups at the 10  4 and 10  8 cell dosages. 
However, at the 10  2 cell dosage, there was actual evidence of enhancement in 
practically  all  of  the  immunized  groups  as  compared with  the  controls.  In 
addition, the mean latent period of some of the immunized groups was quite 
prolonged, indicating that at least some of the enhanced tumors were appearing 
very late. 
Since no immunity was demonstrated upon immunization with dead cells, 
subthreshold doses of live cells,  or subceUular material,  it was  of  interest  to 
ascertain whether immunization could be accomplished by large doses of viable 
adenovirus tumor cells. It was also of interest to detect any cross-reaction be- 
tween mouse and hamster adenovirus 12 transplant antigens, such as has been LEONARD D.  BERMAN  993 
TABLE XI 
Effect of Immunization by Homologous  Whole Cells and Subcdlular Fractions  on  Transplanta- 
tion Immunity to CBA A1 Mouse Adenovirus Tumor 
Experiment  Immunizing agent  Intracerebral cell dose 
XX 
II and XX 
XXXlV 
XX and 
XXVII 
I, IV, and 
XX 
XXVII 
Subthreshold dose (2 X  l0  t live 
tumor cells) 
Heated tumor cells (56°C 30 rain 
Control (untreated) 
1.0--2.0 X  107 ergs 
UV-irradiated (106 cells) 
Control (untreated) 
X-irradiated tumor cells (10  s 
cells) 3600 R  Co  *° irradiation 
Control (untreated) 
Suspension of crude cell debris 
Control (untreated) 
Crude cell extracts 
Control (untreated) 
Various fractions of crude cell 
extracts obtained by differential 
centrifugation 
Control (untreated) 
lO  ~  io* 
5/5*  (42),  3/3  (48) 
5/5  (37)  7/7  (40) 
5/5  (32)  6/6  (45) 
10/12  (40)  6/6  (44) 
9/9  (30)  6/6  (45) 
7/7  (38)  7/7  (75) 
7/7  (32)  6/6  (45) 
10/12  (45)  11/11 (47) 
10/10  (31)  13/13  (41) 
8/11  (66)  10/12  (59) 
9/9  (29)  9/9  (41) 
28/30  (35)  28/29  (43) 
5/5  (30)  7/7  (36) 
10  ~ 
3/3  (67) 
6/6  (48) 
1/6  (42) 
2/4  (48) 
1/6  (42) 
2/5  (88) 
a/6  (37) 
6/12  (78) 
1/13  (42) 
11/13  (53) 
3/lO (58) 
15/29  (71) 
0/7  (-) 
* Incidence of tumors. 
Mean latent period of tumor growth, days. 
TABLE  XII 
E flea of Immunization by Various Hamster Tumors on Resistance of CBA  Miae to A1 Adeno 
12-Indused Tumor 
Experiment  Immunizing tumor  Intracerebral  call dose A1 tumor 
III 
XIII 
Hamster Ad. 12 
Control 
Hamster Ad. 12 
Hamster RSV* 
Hamster MSVt 
Control 
10  j  10' 
7/8 
4/4 
5/6  5/5 
2/4  5/6 
5/5  6/6 
5/5  5/6 
4/5 
5/5 
5/5 
3/5 
* Bryan strain, Rous sarcoma virus. 
Harvey strain, murine sarcoma virus. 994  ADENOVIRUS  TUMOR  SYSTEM 
demonstrated between rat and mouse in the Rous system  (24).  Accordingly, 
CBA mice were implanted with minced fragments of various virus-induced 
hamster tumors, and subsequently challenged with the A1  tumor cells. Some 
of the hamster tumors grew  to  a  size  of  approximately  1 cm  before  being 
rejected. The results are given in Table XII. No immunity was produced by 
heterotransplantation with  the  adenovirus  12  hamster  tumors,  or  with  the 
control Rous sarcoma or murine sarcoma virus hamster tumors. 
DISCUSSION 
The present findings verify the existence of a  virus-induced, virus-specific 
transplantation  antigen  present  in  CBA  mouse  cells  that  have  undergone 
neoplastic transformation by adenovirus type 12. In agreement with findings 
in the polyoma system (25, 26), the present results indicate that the antigen is 
probably a virus-induced cellular antigen, and not a structural virion antigen. 
However, the adenovirus antigen is comparable to a  weak histocompatibility 
antigen, and in distinction to the polyoma and Rous sarcoma systems (27, 28), 
immunization could be more  readily effected by virus  than by homologous 
cellular material. Indeed, at lower doses of  tumor  challenge,  immunization 
with one dose of cellular material appeared to lead to possible tumor enhance- 
ment rather than rejection. 
The  phenomenon of  enhancement is  well known  in  several  experimental 
tumor systems (29,  30).  It is conceivable that in most if not all natural and 
experimental tumor systems, the mechanisms leading to both rejection and 
enhancement come into play, and that a  delicate balance between these two 
alternatives may sometimes exist. In the present series of experimental results, 
in cases where immunization was effected by homologous adenovirus type 12, 
rejection was clearly the ultimate result. This might be explained by the effect 
of large dosage, widespread dissemination, and persistence of antigen. If it is 
postulated  that inoculated virus infects cells,  producing  the  transplantation 
antigen which then immunizes, it is not difficult to conceive that inoculation 
of a high-titered virus preparation will infect many more cells than are present 
in a cellular inoculum, and will disseminate in the host animal to a much greater 
extent, infecting ceils in remote parts of the body, and producing more exten- 
sive contact with the cells of the reticuloendothelial system. 
Inoculation of cellular or subcellular material, on the other hand, provides 
antigen which is of a potentially smaller quantity than that generated by virus 
and which has more of a  tendency to remain localized. Under these circum- 
stances immunization is weaker and slower,  and the stimulus to rejection not 
so pronounced.  Factors leading to enhancement may become dominant under 
these  conditions,  especially where  the  inoculum of tumor  is small  and  the 
initial antigenic stimulus even less. 
The  effect of Freund's adjuvant on the immune response  was  also  quite LEONARD  D.  BEP,  MAN  995 
noteworthy. Although it might be postulated that adjuvant would localize the 
virus,  thus preventing the massive  initial infectious  cycle  described  above, 
inoculations of virus and adjuvant at separate  sites  had the same  effect in 
depressing  the immune rejection response.  It must be noted, however,  that 
evidence of actual enhancement when virus was administered with adjuvant 
was never observed. 
Administration of  oncogenic viruses  with adjuvant or  adjuvant-like ma- 
terials to newborn hamsters has resulted in increased incidence of tumor in the 
case of Rous sarcoma virus (31)  1, or decreased incidence of tumors in the case 
of adenovirus type 12.  3  Administration of Bjorklund type adjuvant-like extracts 
of homologous SV40 tumor in the latent period  after neonatal inoculation of 
SV40 has been  described  as  enhancing  tumor  development  (32, 33), while 
administration of SV40 or adenovirus type 12 to neonatally SV 40-inoculated 
hamsters (34, 35, 36) has diminished  the incidence of tumors.  It appears  that 
the effects of adjuvant on the immune tumor response in mice and hamsters is 
variable,  and the effects of adjuvant in general on the cellular immune response 
of mice and hamsters is poorly understood. It is clear, however, that adjuvant 
has a depressive  effect on the antitumor homograft type immune response in 
adult mice challenged with adenovirus-induced  tumor. This occurs even though 
the  adjuvant-virus-inoculated mice were  actively immunized against virion 
structural antigens,  producing  even  higher  titers of  complement-fixing  and 
virus-neutralizing antibody than mice immunized with virus alone and showing 
transplantation immunity. 
Antibody against the adenovirus  type 12 T  antigen was not found in mice, 
whether they showed immunity against transplantation or not. This,  coupled 
with  the  findings  that immunization with  homologous  tumor  extracts  and 
early infected human cellular  extracts containing abundant T  antigen failed 
to produce immunity, would indicate that the T antigen as well as virion anti- 
gens plays little or no role in transplantation immunity. It would  also confirm 
the  fact  that  T  antigen is  a  weak  antigen,  and  that  continuous massive 
doses in the form of an actively growing tumor mass are needed to maintain 
immunization.  8 
The results of the adoptive and passive  transfer experiments  establish  the 
fact that the bulk of transplantation immunity, at least in the system described 
above,  is mainly mediated through immune lymphoid cells, and that serum 
plays no major role, either by cytotoxicity  or enhancement. However, the tech- 
niques employed for demonstrating serum cytotoxicity or enhancement were 
not very sensitive, and minor degrees of reactivity might have been undetected. 
Lymph node cells were  more  effective  than spleen  cells in their antitumor 
l Allison, A. C. and L. D. Berman. Unpublished observations. 
Berman, L. D., A. C. Allison, and H. G. Pereira. In preparation. 
a Huebner, R. J, L. D. Berman~ and W. T. Lane. Unpublished observations. 996  ADENOVIRUS  TUMOR  SYSTEM 
activity. Appreciable transplantation immunity was  not  achieved by immu- 
nization with heated virus, structural subvirion antigens,  or unrelated viruses. 
This would imply that infectious homologous virus was  necessary for immu- 
ization, and that the reaction was specific for adenovirus type 12 and the closely 
related type 18. Failure to achieve immunization with adenoviruses type 5 and 
7  are  contrary to results  obtained elsewhere  (37,  38)  and might perhaps  be 
explained by the  difference in  experimetal systems employed. 
The present experiments show that it takes at least 2 wk for immunization 
to be fully developed, although some effects were noted after 1 wk. This is in 
line with the expected initiation of a primary homograft response (39). How- 
ever, they fail to shed any light on the questions of possible cross-reaction be- 
tween hamster and mouse transplant antigens. 
The systems used in the present experiments offer many advantages in the 
study of transplantation immunity. Although intracerebral challenge precludes 
the advantage of being able to measure tumor size as an index of resistance, it 
offers  the  advantage  of  working  with  smaller  tumor  challenge  doses  and 
provides a  relatively sharp  end point for titrations.  The banking  of DMSO 
frozen tumor cells in liquid nitrogen combines the advantages of a perpetually 
uniform population of cells with great ease in handling, especially where tissue 
culture of transplant  lines might be difficult to maintain.  These experiments 
show that the A1 tumor cells could be stored frozen for 345 days without any 
loss of tumorigenicity, and that the DMSO medium in the quantities used is 
not injurious to the host animal or growing tumor cells. 
SUMMARy 
The existence of a  virus-induced,  virus-specific transplantation  antigen in 
adenovirus 12-induced CBA mouse tumors was demonstrated. The antigen is 
virus-specific, but not related to structural virion or T  antigens. It is a  weak 
antigen,  and required immunization with whole, infectious adenovirus  12  to 
produce considerable immunity. Comparable immunity could not be  achieved 
with  homologous  cellular  or  subcellular  materials,  but  some  indication  of 
enhancement was produced with low tumor dose. Immunization required at 
least 2 wk and was mediated by immune lymphoid cells.  Serum of immunized 
animals  showed no demonstrable  cytotoxicity or enhancement.  Animals  im- 
munized with virus and Freund's adjuvant showed diminished transplantation 
immunity, although these animals were actively immunized against adenovirus 
type 12 structural virion antigens. 
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EXPLANATION OF PLATE 104 
FIG. 1. Mouse with expanding intracranial tumor showing ruffling of fur and hunch- 
ing of the back. 
Fro. 2. Section of brain of mouse similar to that in Fig. 1. The entire central area 
has been replaced by an expanding tumor mass.  ×  15. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 125  PLATE  104 
(Berman: Adenovirus tumor system) 